"La Clinica Montevergine è da molti decenni punto di riferimento in ambito cardiologico della sanità campana, ed ha cercato costantemente di coniugare al rigore professionale la ricerca di standard di eccellenza, l'attenzione all'innovazione clinica e tecnologica, l'umanizzazione nell'assistenza. Su tali presupposti si è fondata la strategia di garantire “prestazioni prevalentemente di alta specialità e con livelli di qualità elevati”, all’interno di una azienda che autoalimenti obiettivi di qualità e verifiche del risultato, coerenti con indagini di benchmarking, nel rispetto dei parametri scientifici internazionali, dei fondamentali principi etici e deontologici e della compatibilità economica."

During the past decade, Casa di Cura Montevergine conducted 9 clinical trials. In the 10-year time frame, 9 clinical trials started and 2 clinical trials were completed, i.e. on average, 22.2% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 2 clinical trials were completed. i.e. 66.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Casa di Cura Montevergine" #1 sponsor was "Abbott Medical Devices" with 2 trials, followed by "Ettore Sansavini Health Science Foundation" with 2 trials sponsored, "MicroPort CRM" with 2 trials sponsored, "Boston Scientific Corporation" with 1 trials sponsored and "C. R. Bard" with 1 trials sponsored. Other sponsors include 4 different institutions and companies that sponsored additional 14 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Casa di Cura Montevergine" #1 collaborator was "ICON plc" with 1 trials as a collaborator and "Sorin CRM" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "Casa di Cura Montevergine" are "Coronary Artery Disease" (2 trials), "Peripheral Artery Disease" (2 trials), "Acute Coronary Syndrome" (1 trials), "Aortic Valve Insufficiency" (1 trials) and "Aortic Valve Stenosis" (1 trials). Many other conditions were trialed in "Casa di Cura Montevergine" in a lesser frequency.

Most popular intervention types in "Casa di Cura Montevergine" are "Device" (12 trials), "Drug" (2 trials), "Procedure" (2 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "ABSOLUTE™: Self-Expandable Peripheral Nitinol Stent" (1 trials), "Ablation" (1 trials), "Abluminus DES+ Sirolimus Eluting Stent System (SES)" (1 trials), "Aortic Valve Replacement surgery" (1 trials) and "CRT-D" (1 trials). Other intervention names were less common.

The vast majority of trials in "Casa di Cura Montevergine" are 17 trials for "All" genders.

Currently, there are NaN active trials in "Casa di Cura Montevergine". undefined are not yet recruiting, 2 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 9 completed trials in Casa di Cura Montevergine, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Casa di Cura Montevergine, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 6 trials that are defined as “Not Applicable".